摘要 |
In one embodiment, the present invention relates to a new class of ammonium salts of N<SUP>delta</SUP>-acyl derivatives of N<SUP>alpha</SUP>-(4-amino-4-deoxypteroyl)-L-ornithine compounds having a structure according to formula II-IV. Formula II has the structure of: wherein: R<SUP>2 </SUP>represents up to four groups independently selected at each occurrence of R<SUP>2 </SUP>from the group consisting of hydrogen, C<SUB>1-6 </SUB>alkyl, C<SUB>2-6 </SUB>alkenyl, C<SUB>2-6 </SUB>alkynyl, C<SUB>3-8 </SUB>cycloalkyl, C<SUB>1-6 </SUB>alkoxy, chloro, fluoro, hydroxy, and -COOH; R<SUP>3</SUP>, R<SUP>4</SUP>, and R<SUP>5 </SUP>are each independently selected from hydrogen and C<SUB>1-6 </SUB>alkyl; or NR<SUP>3</SUP>R<SUP>4 </SUP>taken combination can form a 5 to 7 member heterocycle having at least one nitrogen ring atom; and x is a real number greater than 0 and less than about 4. The ammonium salts provided by the invention exhibit high inhibitory activity against the growth o methotrexate-resistant cells, and also exhibit superior chemical stability than corresponding acidic N<SUP>delta</SUP>-acyl derivatives of N<SUP>delta</SUP>-acyl derivatives of N<SUP>alpha</SUP>(4-amino-4-deoxypteroyl)-L-ornithine compounds. |
申请人 |
DANA-FARBER CANCER INSTITUTE;ASH STEVENS, INC |
发明人 |
ROSOWSKY, ANDRE;BADER, HENRY;BLUMBERGS, PETER;LIN, MINQTEH |